Articles related to GLYCEMIC CONTROL

Stopping GLP-1 drugs can lead to significant weight regain and increased appetite. Understanding the biological mechanisms and preparing patients for these changes is crucial for effective management.

In a phase 2b trial, plozasiran significantly reduced fasting triglyceride levels at 24 weeks in patients with mixed hyperlipidemia, with the 50 mg quarterly dose achieving a mean reduction of 62.4 percentage points. This study highlights the potential of APOC3 inhibition as a therapeutic strategy for lipid management.

Magnesium plays a crucial role in metabolic health, influencing insulin function and cardiovascular physiology. Addressing magnesium deficiency through dietary changes and supplementation can help manage and prevent metabolic syndrome.

Brazzein, now FDA-approved, emerges as a zero-calorie sweetener potentially safe for diabetic and obese populations, requiring further study to validate its health impacts.

In patients with type 2 diabetes and stage 5 chronic kidney disease, the use of SGLT2 inhibitors is associated with a lower risk of initiating dialysis and experiencing major cardiovascular events, providing a promising therapeutic avenue in a population at elevated risk.

This study highlights the importance of evaluating the nutritional content of plant-based meat substitutes as they compare closely with traditional meats in terms of cardiometabolic health outcomes, with neither showing clear benefits over the other.